The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
 
Thomas Hutson
Employment - Texas Oncology
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst)
 
Dimitry Nosov
Speakers' Bureau - Pfizer
 
Piotr Tomczak
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Oleg N. Lipatov
No Relationships to Disclose
 
Cora N. Sternberg
No Relationships to Disclose
 
Michael N. Needle
Employment - AVEO
 
Tim Eisen
Employment - AstraZeneca
Leadership - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Astellas Pharma; AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche Pharma AG
Research Funding - Bayer; GlaxoSmithKline; Pfizer
Travel, Accommodations, Expenses - Novartis
Other Relationship - Astellas Pharma; AVEO; GlaxoSmithKline; Novartis; Pfizer